Collectively, these findings establish SRXN1 as a critical protumorigenic and prometastatic factor in HCC54, underscoring its promise as a therapeutic target for limiting HCC progression and metastasis. The gene discussed is SRXN1; the disease is hepatocellular carcinoma.